唑吡坦片对冠状动脉介入手术患者住院费用的影响

目的观察唑吡坦片对冠状动脉介入手术患者住院费用的影响。方法采用前瞻性随机双盲对照的方法，将246例拟诊为冠状动脉粥样硬化性心脏病而择期行首次冠状动脉介入手术的患者，分为安慰剂组（122例）或唑吡坦片治疗组（124例）。所有患者均于入组当晚开始每晚睡前服用唑吡坦片5mg或外形、性状类似于治疗药的安慰剂，三天后行冠状动脉介入治疗。所有患者均于术前24小时内行中国版90项症状清单（SCL-90）评价。结果两组间年龄、体重、烟酒嗜好等比较差异无统计学意义（P〉0．05）；两组间合并高血压和糖尿病的人数差异无统计学意义（均P〉0．05）。与对照组比较，唑吡坦片组冠状动脉介入术前患者躯体化、焦虑、恐怖、精神病性和总均分等项目评分均有明显下降，差异均有统计学意义（P〈0．05，〈0．01）。与对照组比较，唑吡坦片组的住院时间和住院费用显著减少，差异有统计学意义（P〈0．05）。结论术前服用唑吡坦片可改善冠状动脉介入手术患者的心理状况，减少患者住院时间，降低住院费用。

Effects of Zolpidem Tartrate on Hospital Expenses of Patients undergoing Coronary Intervention Surgery

Objective To explore the effects of Zolpidem Tartrate on hospital expenses of patients undergoing coronary intervention surgery. Melhods A prospective, randomized, double-blind, placebo-controlled study was carried out. 246 patients with coronary atherosclerotic cardiopathy undergoing coronary intervention surgery firstly were randomized into control group given placebo （n = 122） and treatment group were given Zolpidem Tartrate （n = 124）. All patients took Zolpidem Tartrate of 5mg or placebo with similar size and trails. Three days later, coronary intervention surgery was operated on all patients. Before 24 hours of surgery, all patients were evaluated by symptom checklist 90 （SCL-90） of Chinese. Results No significant differences were found in age, weight, habit of smoking and drinking, diabetes and hypertension between two groups （P 〉 0.05）. There were no significant differences in numbers of patients with hypertension and diabetes. Comparing with the control group, the grade of somatization, anxiety, phobia, psychosis of patients with treatment of Zolpidem Tartrate were significantly reduced before surgery （ P 〈 0.05, 〈 0.01 ）, and the hospital ex- penses and duration of hospitalization were also significantly reduced（ P 〈 0.05）. Conclusions Taking Zolpidem Tartrate before surgery may improve the psychology of patients, reduce the hospital expenses and duration of hospitalization.